Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to $505 from $515 on April 13, reiterating a Buy rating on the shares. The rating update came as part of a broader research note previewing Q1 results among Biotech names. The firm told investors in a research note that although management was confident in robust year-over-year growth, it cautioned for fiscal Q1 seasonal weakness in the United States from typical payer dynamics and 2 fewer shipping weeks.

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

In a separate development, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition and improving care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The company is advancing, through complementary initiatives with Viz.ai and the American Heart Association, a comprehensive, system‑level approach addressing the continuous challenges of underdiagnosis and fragmented care in ATTR‑CM.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biopharmaceutical company that develops and commercializes novel therapeutics based on ribonucleic acid interference.

While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.